The genomic catalogue of the human microbiota has expanded dramatically in recent years, 22 and insights derived from human microbiota genomics has vast potential to generate treatments 23 for human diseases. However, predictably harnessing the microbiota for beneficial outcomes is 
Overall, our experimental data is in strong agreement with previous findings for several PULs.
233
We identified specific and important phenotypes for at least 3 genes from multiple PULs on their 234 predicted or known polysaccharides ( In addition to confirming the results of these previous studies, we provide the first genetic The first new GAG utilization gene we identified was BT4411, which was important for growth 307 on HA but not on CS ( Figure 6A ). BT4411 is predicted to be in the same operon as the CS lyase 308 BT4410, which was also more important for fitness on HA. BT4411 contains a domain of 309 unknown function, DUF4627, which to our knowledge has not been previously characterized. Finally, we found that BT3233 was important for growth on 3 GAGs: CS (fitness = -1.8 and -1. Figure 3) . In addition, in each of these three species, at least one copy substrates from outside the cell to the periplasmic space, no growth deficiency was found in any 507 of the carbohydrate conditions that we assayed. To validate our genome-wide data, we assayed 508 the growth of a BT1439 deletion mutant and found that it was substantially more resistant to 509 vancomycin relative to the parental control ( Figure 9DE ). The concentration of vancomycin that 510 inhibited growth by half (IC50) was over seven times higher in the BT1439 mutant compared to 511 the non-mutated control (0.0047 versus 0.00066 mg/mL) (Supplementary Figure 4) . 512 Interestingly, the vancomycin phenotype of BT1439-1440 was only observed in BHIS media, 513 and not in VB media ( Figure 9C 
